AI-enabled Screening and Diagnosis of Cardiomyopathies Using Coronary CTA

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorShanghai Zhongshan Hospital

About this trial

The goal of this observational and diagnostic study is to develop and validate an artificial intelligence assisted approach for coronary computer tomography angiography-(CCTA)-based screening and diagnosis of cardiomyopathies in patients with suspected coronary artery diseases. This study aims to develop a computerized CCTA interpretation using artificial intelligence for multi-label classification task to assist cardiomyopathy diagnosis in the clinical workflow.

Eligibility criteria

Qualifiers

A clinical diagnosis of cardiomyopathies, including hypertrophic cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy, cardiac amyloidosis, myocarditis, arrhythmogenic right ventricular cardiomyopathy, and coronary artery disease/ischemic heart disease.

At least one CCTA before surgery or implantable device treatment.

Disqualifiers

No recorded diagnosis of cardiomyopathy or undetermined type of cardiomyopathy.

A clinical diagnosis of secondary cardiac abnormalities due to other organic or systemic diseases.

Surgery or implantable device treatment before CCTA examination.

Inclusion Criteria: participants with at least one CCTA examination.

Trial design

Treatments tested in this trial

  • CCTAI model

Treatment groups

5,000 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators